JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

ABSTRACT: This study is to evaluate the safety and tolerability of JAB-21822 monotherapy and combination therapy in adult participants with advanced solid tumors harboring KRAS G12C mutation.

DISEASE(S): Nsclc,Crc,Phase 1: Advanced Solid Tumors, Relapsed Or Refractory To Standard Therapyphase 2: Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, And Other Solid Tumors,Advanced Solid Tumor,Fase 1: Tumores Sólidos Avanzados, Recidivantes O Refractarios A Terapia Estándarfase 2: Cáncer De Pulmón No Microcítico, Cáncer Colorrectal Metastásico Y Otros Tumores Sólidos,Neoplasms

PROVIDER: 2386408 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR